It's up to Indian drugmakers to match the expectations of the U.S. FDA not only for product quality but for record-keeping and operations as well, Shishir Asthana writes. Almost 40% of generic medicines marketed in the U.S. come from drugmakers in India, and increased scrutiny and inspections may feel like victimization, but they are not, he writes.

Related Summaries